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Background: Despite major public health initiatives and the existence of efficacious treatment regimes,
tuberculosis (TB) remains a threat, particularly in resource-limited settings. A significant part of the problem is the
difficulty of rapidly identifying infected individuals, and as a result, there has been renewed interest in developing
better diagnostics for infection or disease caused by Mycobacterium tuberculosis. Many of the existing tools,
however, have limitations such as poor sensitivity or specificity, or the need for well-equipped laboratories to
function effectively. Serodiagnostic approaches in particular have long drawn attention, due to their potential utility
in large field studies, particularly in resource-poor settings. Unfortunately none of the serodiagnostic approaches
have so far proven useful under field conditions.
Results: We screened a large panel of antigens with serodiagnostic potential by ELISA and selected a subpanel that
was strongly and broadly recognised by TB patients, but not by controls. These antigens were then formulated into
a simple immuno-chromatographic lateral flow assay format, suitable for field use, and tested against panels of
plasma and blood samples from individuals with different clinical status (confirmed TB patients, household contacts,
and apparently healthy community controls), recruited from Ethiopia (a highly TB-endemic country) and Turkey (a TB
meso-endemic country). While specificity was good (97-100% in non TB-endemic controls), the sensitivity was not as
high as expected (46-54% in pulmonary TB, 25-29% in extra-pulmonary TB).
Conclusions: Though below the level of sensitivity the consortium had set for commercial development, the assay
specifically identified M. tuberculosis-infected individuals, and provides a valuable proof of concept.
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reproduction in any medium, provided the or(among HIV-negative cases of TB) in 2010 [1]. In addition,
Mycobacterium tuberculosis is estimated to infect about a
third of the world population, and although the vast major-
ity contain the infection without clinical manifestations of
the disease [2,3], they are at risk of later reactivation, and
can act as reservoir for future disease [4]. The majority of
TB cases in developing countries are still diagnosed using
smear microscopy and clinical examination, augmented by
chest X-ray. The use of X-ray examination is often re-
stricted to advanced pulmonary TB in resource-limited set-
tings, and the sensitivity of smear microscopy is in theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pulmonary TB patients [5]. Newly-developed diagnostic
tools such as whole blood interferon gamma (IFN-γ) re-
lease assays (IGRAs) and real time polymerase chain reac-
tion (PCR)-based GenXpert [4,6-8] are unsuitable for
routine clinical use in resource poor settings, where the
majority of TB cases occur, as many of these techniques re-
quire sophisticated laboratory set-ups, equipment and
trained personnel. In particular, the lack of tests that can
be used at point of care (POC) is a major impediment to
effective TB diagnosis.
In recent years, TB serological tests have drawn atten-
tion because of their potential to be developed for POC
use. Unlike cell-mediated immune responses, the humoral
response to M. tuberculosis is often delayed and peaks
much later, possibly coinciding with the onset of clinical
disease [9]. A specific, sensitive TB serodiagnostic test in a
rapid test format could therefore constitute the ideal sup-
plement for current diagnostic approaches in highly TB-
endemic countries. Considerable progress has been made
in the identification of M. tuberculosis antigens with the
help of comparative genomics [10-12], and several prom-
ising antigens have been identified for use in serodiagnosis
[13,14]. The main objective of this study was to screen
and evaluate a broad panel of M. tuberculosis antigens and
identify candidates for construction of an antibody-based
immuno-chromatographic lateral flow assay (LFA) in a
field-friendly format applicable in point of care screening.
The best candidates from the screening panel were then
converted to a simple LFA, which could be read without
the need for further laboratory equipment, and tested
against blood and plasma samples from study cohorts
with well-defined clinical status.
Methods
Study design and participants
This study was performed on plasma samples collected
after written informed consent was obtained from mul-
tiple sources, including:
119 HIV-negative TB patients recruited at Danish
hospitals,
79 HIV-negative TB patients recruited at Ethiopian
hospitals,
99 HIV-negative TB patients recruited at Turkish
hospitals,
79 HIV-negative TB patients from Uganda obtained
through the WHO/TDR Tuberculosis Specimen bank,
73 close household contacts (HIV-negative) recruited
among the families of patients from Ethiopian
hospitals,
48 Mantoux-positive, close household contacts (HIV-
negative) recruited among the families of patients from
Turkish hospitals,79 non-endemic healthy, HIV-negative controls with no
known exposure to TB, recruited from the same
communities in Denmark as the TB patients,
58 TB-endemic HIV-negative healthy controls, recruited
from the same communities in Ethiopia as the TB
patients,
153 TB-endemic HIV-negative healthy controls, recruited
from the same communities in Turkey as the TB patients,
8 extra-pulmonary TB patients and 8 symptomatic non-
TB community controls, recruited from Turkey and
31 extra-pulmonary TB patients from Ethiopia.
The TB patients were newly diagnosed, bacteriologic-
ally confirmed (smear- and/or culture positive, from
sputum or needle aspirate) clinical cases with persistent
cough for more than 2 weeks, accompanied by signs and
symptoms of TB such as productive cough, loss of appe-
tite, weight loss, night sweat or haemoptysis, enlarged
lymph nodes or abnormal chest X-ray. Household con-
tacts were defined as individuals who had been living
with pulmonary TB (PTB) patients in the same house-
hold at least for the past 6 months before recruitment into
the study. The majority of these cases were apparently
healthy, asymptomatic, and had normal chest X-rays.
However, 12 cases had complaints of cough and abnormal
chest X-ray (16%), albeit not serious or specific enough for
them to be diagnosed as having TB, and were sputum
negative. The control groups were apparently healthy vol-
unteers, living in the same community with TB patients.
All participants were screened for HIV and were negative.
This study received ethical approval from institutional and
national ethical review committees of all partners in-
volved: the Statens Serum Institute IRB, København
Kommunes Videnskabsetiske Komité in Copenhagen, the
Scientific Ethics Committee in Refik Saydam National Hy-
giene Centre, Ankara and the National Health Science
and Technology Council and ethics review committees in
Addis Ababa (the AHRI/ALERT Ethics Review Commit-
tee and the National Research Ethics Review Committee
of Ethiopia).
Antigen selection and plasma sample preparation
The Statens Serum Institute (SSI) in Denmark produced
over 100 TB antigens, identified potential antigens for
use in serodiagnosis, and supplied all the antigens evalu-
ated in this study. The bulk of the antigen screening has
already been published [15-19] and so will be only
briefly described here. From the initial screening process
[15-18], we selected 10 antigens, which had demonstrated
potential for further analysis. Subsequent rescreening
using sera from Denmark, Uganda and Gambia identified
4 candidate antigens (Table 1) that had demonstrated high
specificity (95%) and tolerable sensitivity (recognized by
over 30% of TB patients). The hope was a combination of
Table 1 Percent antibody positive responders by ELISA in different population groups to candidate antigens
Antigen Healthy controls
(Denmark, n = 79)
TB patients
(Denmark, n = 119)
TB patients
(Uganda, n = 77)
Healthy controls
(Ethiopia, n = 58)
TB patients
(Ethiopia n = 79)
ESAT-6: CFP10 3 45 91 31 74
TB16.3 4 38 56 ND ND
MPT83: Acry 4 72 74 19 64
CYP15 4 10 30 17 72
CFP21 8 35 50 34 46
Rv1575 18 28 67 50 62
ORF3 5 15 55 16 71
CFP8A 6 38 74 28 53
Rv3118 15 28 72 ND ND
Rv0222 3 74 89 25 78
A positive result was defined as the negative control (serum without antigen), plus 3 standard deviations as previously described [18]. Those antigens selected for
further development in the LFA are written in bold.
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whole. The antigens selected for the SERO-TB study in-
clude a fusion hybrid of the two most characterized pro-
teins, ESAT-6: CFP10 (also called Diaser-3, Rv3875:
Rv3874), CFP-8a (Rv3354), ORF-3 (Rv3872) and MTB:
Acry (Rv2873: Rv2031c). The antigens were expressed in
Escherichia coli (E. coli) vectors and purified as described
earlier [15].
Since the antigens were expressed in an E. coli vector,
all plasma samples were adsorbed against E. coli Extract
(Promega, San Luis Obispo, CA, USA), to reduce
nonspecific responses, according to the manufacturer’s
recommendations. Briefly, 20 μl of E. coli extract was
added to 200 μl of plasma sample, incubated overnight
(O/N) at room temperature (RT), with gentle shaking.
The day after, the mix was centrifuged at 10,000 rpm for
10 min and the supernatant transferred into new tubes,
where it was treated with 0.05% sodium azide to prevent
growth of contaminating bacteria. The samples were
then kept at 4°C until use. As a control, a subset of
plasma samples were tested against the test antigens be-
fore and after adsorption (Additional file 1).
In short, antigens were coated in duplicate onto 96-well
polystyrene microtiter plates (Nunc, Roskilde, Denmark)
at concentrations ranging from 5 to 0. 1 μg/ml in 100 μl
of 0.05 M carbonate buffer (pH 9.6) and then incubated
overnight at 4°C. After the plates were coated, they were
washed three times with phosphate-buffered saline (PBS;
pH 7.2)–0.05% Tween 20 (PBS-T), and serum samples
diluted 1:100 in 0.2% PBS-T and 1% bovine serum al-
bumin were applied and incubated for 1 hour at room
temperature. The plates were then washed with PBS-T,
and then incubated for 1 hour with rabbit anti-human
immunoglobulin G antibody conjugated with horseradish
peroxidase (D0336; Dako, Hillerød, Denmark) diluted
1:1,000 in PBS-T. The plates were washed with PBS-T and
enzyme activity was assayed by incubation for 30 min atroom temperature with 100 μl of tetramethylbenzidine
peroxidase substrate (Bio-Rad, Hercules, Calif.) per well.
To stop the reaction, 100 μl of 4 N sulfuric acid was added
and the optical density (OD) was measured at 405 nm. In
each experimental plate, known concentration of purified
human IgG immunoglobulin (rhIgG) (SIGMA) was seri-
ally diluted and run as standard (positive control) along
with samples and blank wells as negative controls. OD
values were then measured, concentrations extrapolated
against known concentration of standard (rhIgG) using
GraphPad Prism Software (Version 4.0).
Multi-antigen print immunoassay
Antibody determinations were done by multi-antigen
print immunoassay (MAPIA) as described previously [20].
Briefly, the 4 antigens of interest were immobilized on
nitrocellulose membrane (Schleicher & Schuell, Keene,
NH) at a concentration of 0.05 mg/ml using a semi-
automated microsprayer (Linomat IV, Camag Scientific
Inc., Wilmington, DE). The membrane was cut perpendicu-
lar to the antigen bands into 4 mm wide strips, blocked
(1 h) with 1% non-fat skim milk in PBS-T and then
incubated for 1 h with serum samples diluted 1:50 in
blocking solution. After washing, strips were incubated
(1 h) with alkaline phosphatase-conjugated anti-human IgG
or anti-human IgM antibody (Sigma Chemical Co., St.
Louis, MO) diluted 1:5000 in blocking solution, followed by
washing. Bound antibodies were visualized with BCIP/NBT
(Kirkegaard & Perry Laboratories, Gaithersburg, MD).
Lateral flow assay (LFA) production
The clones for recombinant expression of CFP8A,
ORF3, CFP10: ESAT-6 and Acry: MPT83 were provided
by SSI to Vircell on the pMCT6 plasmid vector, along
with the recombinant proteins for comparison and anti-
bodies against the target antigens in order to confirm ex-
pression and purification of the correct product. The
A B C D E
Figure 1 Recombinant antigens after purification. SDS-PAGE gel
of the recombinant proteins prepared for spraying onto
nitrocellulose. A: Molecular weight markers. B: ORF3. C: ESAT. 6:
CFP10. D: MPT83: Acry. E: CFP8A.
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ously described Skjøt et al., 2000, Rosenkrands, 2008.
The genes for each of the selected target molecules were
transformed into the E. coli BL21 strain Rosetta(DE3)
pLysS (EMD4Biosciences) to provide expression of the
mycobacterial genes which should not be limited by the
codon usage of E. coli. Since pMCT6 is not optimised as
a high yield expression vector, and provided low expres-
sion levels in XL1-Blue, the genes were subcloned. For
the initial transformations, the expression plasmid
pQE60 was used -subsequently, XL1-Blue (Stratagene)
transformed with the pREP4 vector (Invitrogen) was
used for expression. However, since the yield of some of
the recombinant proteins was very low, the heterologous
genes were transferred to a different expression vectors
in order to improve expression. In the case of ORF3, the
expression vector used was pET-15b (Novagen). For
CFP8A, an expression vector constructed in Vircell was
used, pET-His. Inserted genes in both vectors were
under the control of the T7 RNA polymerase promoter
and added a hexamer his-tag at the N-terminal of the
produced protein. These two new constructions were
transformed into the strain of E. coli Rosetta(DE3)pLysS,
an expression strain which contains a chromosomal
copy of the T7 RNAP gene, under the control of the
lacUV5 promoter, which can be induced by IPTG. Post-
induction, the proteins were collected by centrifugation,
followed by lysis of the bacterial pellet and purified
under denaturing conditions as previously described
[21]. Briefly, denatured proteins were applied to nickel
affinity columns (Talon columns; Clontech) and washed
with three column volumes of wash buffer (4 M guanidine-
HCl, 50 mM sodium phosphate [pH 7.2], 300 mM NaCl).
The recombinant proteins were thereafter eluted by adding
three column volumes of the wash buffer supplemented
with 150 mM imidazole. Flowthrough wash and eluates
were collected and selected fractions were pooled after
examination on Coomassie blue-stained sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE)
gels (Figure 1). All proteins were then dialyzed against a
20–50 mM phosphate buffer pH 7.5 with 150 mM NaCl to
a final concentration of 1 μg/ml, and sprayed onto a nitro-
cellulose membrane using a Linomat IV microsprayer
(Camag Scientific Inc.) at 1 μl/cm2. The membrane was
dried overnight at 37°C, attached to an adsorbent pad at
one end (to wick fluid) and to a conjugate pad overlapped
by an absorbent sample pad at the other end. The mem-
brane and absorbent pad unit were immobilized in a plastic
case (see Figure 2).
Application of selected antigens to the lateral-flow format
The LFA works on the principle of labelling and captur-
ing antibodies from a blood or serum sample applied as
they flow through a membrane and concentrating thelabel on a line of antigen bound to the membrane so
that it becomes visible. If the serum contains antigen-
specific antibody, it will react with the immobilized re-
combinant protein on the testing line, as it migrates
through the nitrocellulose membrane, to give rise to a
purplish band, the intensity of which will be propor-
tional to the concentration of antibody. For a final pro-
duction version, a control line of anti-human IgG would
have been incorporated at the end of the nitrocellulose
to ensure that the sample fluid had crossed the antigen
line(s) and as a control on manufacturing quality and
that the serum applied was of human origin, but in the
test version, this was omitted and fluid transfer simply
checked by eye. In addition, multiple antigens would be
applied, to increase the sensitivity of the test. Based on
initial screening, four antigens with sensitivity of greater
than 50% in TB patients from TB-endemic regions were
selected to form the basis of the test, which when com-
bined, were predicted to give better than 90% responsive-
ness among TB patients (Table 1, [15]) while retaining a
high degree of specificity. Initial screening using a multi-
antigen print immunoassay (MAPIA) ensured that the an-
tigens were also recognised when bound to nitrocellulose
(Figure 3). Initial test results indicated that the prototype
LFA gave a clearly positive result with each antigen,
though not all TB patients tested in the initial MAPIA
screen (Danish TB patients, n = 10) responded to all anti-
gens, and no reactivity was seen with negative controls
(Danish BCG-vaccinated negative controls, n = 15). How-
ever, since the goal of this study was to assess antigen po-
tential for inclusion in a LFA, each antigen was initially
ESAT-6:CFP10 MPT83:Acry
Figure 2 Serum titration on LFA prototype. For testing prototypes, a positive control pool of sera from Ugandan TB patients, all with sputum-
confirmed tuberculosis and ELISA-confirmed reactivity against one of more of the test antigens was prepared, aliquoted and frozen. A negative
control pool was likewise prepared from Danish donors with no known risk factors for TB and no known exposure, all of whom had been
confirmed negative for the test antigen by ELISA. A typical result, showing titration of the positive control pool from 1:1 to 1: 8 (left to right), with
diluent-only control in the 5th lane of each test to the right.
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specimen diluted in PBS was added to the sample cham-
ber and after 15 min, the results were considered positive
(if a band was present at the line where the antigen had
been applied. In all cases, the most intense staining was
seen with sera from TB patients at the lowest dilution
(Figure 2). Specificity was assessed the same way using
100 control sera from Jaén (Spain) and El Ejido (Almeria,
Spain). The use of negative controls reduced the possibil-
ity of positive results in the control group due to unidenti-
fied TB exposure. We saw little evidence of non-specific
staining by non-TB patients at any serum dilution – only
three controls were positive against any of the antigens
and the staining seen was weak. A study to determine if
there was a prozone effect, using concentrated mono-
clonal antibodies against the antigen targets showed no
such effect (Additional file 2). A study was also conducted
to determine the effect of interference due to hemoglobin
(which can be a potential problem if lysis of the red blood
cells occurs during a blood draw). Different dilutions of
hemoglobin (up to 500 mg/dl) were tested, together
with the negative and positive control antibody pools.Figure 3 Antigen screening using multi-antigen print immunoassay. S
controls (Danish participants, no known TB exposure of TB risk factors) and
nitrocellulose strips were incubated with sera diluted 1/50 in 1% non-fat skHemoglobin did not affect the immunological reaction,
or its visibility, though at higher concentrations it did
produce generalized pinkish staining of the membrane
(Additional file 3).
Once the basic parameters were established, the proto-
type LFAs was assessed for stability and reproducibility
in use. Stability was tested at room temperature and at
2-8°C as well as via an accelerated stability study. The
stability studies at room temperature (20-25°C) were
assessed at 15 days, 1 month, 3 months and then every
subsequent three months for 18 months. The perform-
ance of the kit at 2-8°C was tested every three months
for 18 months. The accelerated stability study was car-
ried out by incubating the LFAs at 37°C and 55°C in a
humid atmosphere. Testing was performed at 3, 7, 10,
15, 21, and 30 days at 37°C as well as at 3, 7, 10, and
15 days at 55°C. On each of the indicated days, dilutions
of the positive sera pool (from 1:1 to 1:16) were analyzed
in duplicate alongside the undiluted negative control
pool. For LFAs stored at room temperature, 2-8°C or at
37°C, there was no significant decay of the signal during
the testing period, while at 55°C, the intensity of thetaining of antigen printed onto nitrocellulose by sera from 5 negative
19 patients with confirmed TB, recruited from Danish hospitals. The
im milk in PBS-T.
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at or below 1/4 dilution were clearly weaker in color in-
tensity than the same samples assessed earlier in the
study. Finally, reproducibility was tested on three differ-
ent days, performed with three different sample titra-
tions, and a positive and negative control. The prototype
showed excellent reproducibility across different days,
samples and operators (Additional file 4). Following
these assessments, the LFA test kits were sent to Turkey
and Ethiopia for testing under field conditions.
Data analysis
Raw data was measured as OD values and the concentra-
tion of IgG in each sample was extrapolated from the
standard curve drawn from human rhIgG standard, using
GraphPad Prism Software (Version 4.0), with assumption
of a non-linear regression model and Sigmoidal-dose re-
sponse (variable slope) equation. Comparison between
groups was done using one-way ANOVA with the as-
sumption of Kruskal-Wallis test statistics. A p-value < 0.05
was taken as indicating statistical significance.
Results
Results of the lateral flow test under field conditions
Reports from both sites indicated that the test was well
accepted by staff, being simple to use, requiring little
extra equipment and producing results after 20–30 mi-
nutes. Blood was taken by thumb prick into a 1.5 ml
eppendorf tube, allowed to clot, and 50 μl of the sera
taken with a micropipette. This was added to the LFA,
followed by 50 μl of PBS. The test was then allowed to
stand for 15 minutes, at which point, the results were
read. The results from Turkey, where the LFA was tested
with sera from 99 TB patients, 48 household contactsTable 2 Individuals responding to candidate antigens from cl
Results from Turkish clinical cohorts
Cohort Clinical definition
TB patients (n = 99) Pulmonary (n = 91)
Extra-pulmonary (n = 8)
TB contacts (n = 48) PPD+, known exposure (n = 48)
Community controls (n = 153) Symptomatic, non-TB (n = 8)
Healthy, no identified exposure (n = 145)
Results from Ethiopian clinical cohorts
Cohort Clinical definition
TB patients (n = 79) Pulmonary (n = 48)
Extra-pulmonary (n = 31)
TB contacts (n = 73) Known exposure (n = 73)
Community controls (n = 60) Healthy, no identified exposure (n = 60)and 153 community controls are presented in Table 2.
The association of positivity with presumed exposure to
TB (Table 2) suggests that the LFA retained the high de-
gree of specificity seen in laboratory testing. However,
the overall sensitivity was disappointing, with only 46%
of the TB patients testing as positive for any one antigen –
as compared to 93% who were positive for the Mantoux
test at a cut-off of 15 mm. Of the TB household contacts,
38% were positive for at least one antigen (versus 100%
positive by Mantoux), while for the community controls
12% were positive for at least one of the antigens in the
LFA, versus 5% in the Mantoux test. As can be seen in
Table 2, the majority of positive responses were directed
against the MPT83: Acry fusion molecule. Although the
sample size is too small to draw conclusions, among the
99 TB patients were 8 with extra-pulmonary TB. Of these,
only 2 gave a positive test in the LFA – both to the
MPT83: Acry fusion molecule.
In Ethiopia, the results were very similar. Of the 79
index cases, 48% were positive for one or more antigens,
compared to 29% of household contacts and 27% of
community controls. The Ethiopian TB patient cohort
included 48 pulmonary tuberculosis patients and 31
extra-pulmonary tuberculosis patients with needle-
aspirate confirmed tuberculosis lymphadenitis, but al-
though the percentage of responders were lower in the
latter group, there were no clear differences between the
groups in terms of antigen recognition in the LFA. The ob-
servation that a significant number of healthy controls
were positive for one or more antigens in the LFA is the
only point at which the Ethiopian data diverge from the
Turkish data set, and this is consistent with earlier studies
in this highly TB-endemic community, which have sug-
gested that over 30% of adult Ethiopian communityinical cohorts in Turkey and Ethiopia
Number (percentage) responding to antigen
ESAT-6 CFP8A Acr: MPT83 ORF3 Any antigen
17 (18.6%) 9 (9.8%) 40 (43.9%) 5 (5.5%) 45 (45.5%)
0 (0%) 0 (0%) 2 (25%) 0 (0%) 2 (25%)
4 (8.5%) 2 (4.2%) 16 (33.3%) 2 (4.2%) 18 (37.5%)
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
6 (4.2%) 2 (1.4%) 15 (9.1%) 1 (0.7%) 18 (11.8%)
Number (percentage) responding to antigen
ESAT-6 CFP8A Acr: MPT83 ORF3 Any antigen
9 (18.8%) 5 (10.4%) 24 (50.0%) 0 (0%) 26 (54.2%)
4 (12.9%) 2 (0.65%) 12 (38.7%) 0 (0%) 12 (38.7%)
4 (8.48%) 2 (4.16%) 19 (26.0%) 0 (0%) 21 (28.8%)
6 (4.19%) 2 (1.39%) 12 (20.0%) 0 (0%) 16 (26.7%)
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not available from Ethiopia as this test is not routinely used
in the local clinics, but the results suggest that the test does
not differentiate latent and acute M. tuberculosis infection.
Again, in all cohorts MPT83: Acry was by far the most fre-
quently recognised target, which was unexpected, given
the high seropositivity to ESAT-6: CFP10 observed in this
population by ELISA [15]. The results (Tables 1 and 2) sug-
gest that the findings seen with the LFA are a result of this
particular test formulation’s technical performance, not
due to an absence of specific antibody in the participants
in the study.
Discussion
In resource-poor settings, the diagnosis of TB is primar-
ily based on identification of mycobacteria by sputum
smear and on clinical evidence. However, bacteriological
examination is often time-consuming and relatively in-
sensitive. Better tools are available, but are often imprac-
tical due to their cost, technical requirements or the
long waiting times required for the diagnostic result. Al-
though the potential for antibody-based diagnostic tools
to give a quick answer using a simple blood draw has
made them attractive alternatives for TB diagnosis,
current test formats have proven ineffective, due to their
low sensitivity and specificity [9] and the fact that many
of them still require laboratory infrastructure. Concern
over the poor accuracy of available commercial sero-
logical tests has been raised by the WHO [23,24]. The
single most important factor for the failure of the
current serological tests is the choice of antigens used,
the majority of which are shared with other mycobac-
teria leading to low specificity in individuals living in the
developing countries. Many of the antigens are also rela-
tively weakly recognized, accounting for the poor sensi-
tivity of these tests.
We have addressed these problems systematically, by
screening a broad panel of antigens and select those
which were best recognized [15-18]. We also identified
that antigens that had limited specificity for M. tubercu-
losis infection, by screening with negative controls from
both TB-endemic and non-endemic countries. The se-
lected antigens were used to develop an LFA, with the
goal of providing a serological test that was inexpensive,
simple and suitable for point of care use. Since issues re-
garding sensitivity and specificity are the major factors
that determine the applicability of such test kits [25],
particularly in resource limited settings, validation of
such tools in different settings is warranted.
Several important observations have been made in the
course of this work. Consistent with prior reports [15]
although a higher percentage of TB patients had a sig-
nificant antibody response to the specific antigens
chosen for the LFA in the ELISA, there were still asignificant number of healthy controls from TB-endemic
populations who made positive responses to these anti-
gens (Table 1). Given that prior studies have indicated a
high rate of latent infection in this population [22] and
the low percentage of responders to these antigens
among healthy controls from a non-TB-endemic coun-
try, it is likely that this response is indicative of latent
TB infection, rather than cross-reactivity. Nonetheless, it
poses a problem for using such tests in TB-endemic set-
tings, where the ideal would be to identify active or in-
cipient TB, not just M. tuberculosis infection.
Interestingly, the hierarchy of responses observed in
ELISA did not predict the outcome in the LFA. When
ranked in terms of the percentage of TB patients who
made a significant antibody response, TB patients from
TB-endemic regions (Uganda and Ethiopia) responded
most frequently in the ELISA to the ESAT-6: CFP10
dimer, with a lower percentage responding to the
MPT83: Acry dimer. When testing these same antigens
in the LFA, this response was completely reversed, with
a greatest number of responders being found to the
MPT83: Acry dimer. It is not clear if this is a question
of avidity, conformational change when the antigens are
bound, or some as yet unidentified interference, but it
strongly suggests that screening results using ELISA
may not always be predictive for other assay formats, in-
cluding LFA. In addition, we did not recruit sufficient
HIV positive individuals to conduct any meaningful ana-
lyses in this study, but given the high risk of TB in HIV
positive individuals, this is certainly an area that should
be further explored.
Conclusions
The results presented here represent one of the few re-
ports on the testing of an LFA designed to diagnose hu-
man TB and provide an important proof of concept. It
should be noted that despite the relatively low sensitiv-
ity, the test does appear to have a high specificity (over
95%, when assessed against the negative controls from
Denmark and Spain, who can be safely assumed to be
mostly free of M. tuberculosis infection). Since the mole-
cules most frequently recognised in these studies (ESAT-6:
CFP10 and MPT83: Acry) gave a sensitivity of over 90% in
an LFA developed for primate use [26], these results sug-
gest that with further optimisation, a point of care LFA test
could be developed for rapid diagnosis of human TB,
perhaps using different antigens [27,28]. It has been
suggested that allowing serum antibodies to bind to
antigen prior to detecting the antibody-antigen com-
plexes as a second step (as opposed to having anti-
bodies interact with the conjugate prior to antigen
binding, as occurs in this assay), can improve the sen-
sitivity of the assay and it may also be possible to im-
prove the signalling conjugate used. Given the ongoing
Wassie et al. BMC Research Notes 2013, 6:202 Page 8 of 9
http://www.biomedcentral.com/1756-0500/6/202need for a simple, inexpensive point of care test for
TB, these options should be further investigated.Additional files
Additional file 1: As a control, a subset of plasma samples were
tested against the test antigens before and after adsorption: no
significant differences were seen. As an example, the next tables
gather the results corresponding to operator#1. The test strips (here
identified as T#1, T#2, etc) were provided unlabelled, so that the operator
was not aware of which tests were being read. The notation used reflects
scoring against the test strip (marked 2, 1, 0.5 and 0 in order of
decreasing intensity), where an arrow is used to indicate slightly greater,
or slightly less than, the indicated value.
Additional file 2: A study to determine if there was a prozone
effect, using a concentrated monoclonal antibodies against the
antigen targets showed no such effect (typical response using
monoclonal Ab against MPT83 titrated from 1/1-1/16 shown: strip
with ORF3 used as negative control).
Additional file 3: Hemoglobin did not affect the immunological
reaction, or its visibility, though at higher concentrations it did
produce generalized faint pinkish staining of the membrane
(Typical result at highest concentration shown below).
Additional file 4: Reproducibility was tested by three different
operators at three different days each, performed with three
different levels (positive sample dilutions), and a positive and
negative control respectively. The prototype showed a good
reproducibility between days, samples and operators. As an example, the
next tables gather the results corresponding to operator#1. The test strips
(here identified as T#1, T#2, etc) were provided unlabelled, so that the
operator was not aware of which tests were being read. The notation
used reflects scoring against the test strip (marked 2, 1, 0.5 and 0 in order
of decreasing intensity), where an arrow is used to indicate slightly
greater, or slightly less than, the indicated value.Competing interests
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